Merck & Co.'s SWOT analysis: stock faces keytruda LOE, china challenges

Merck & Co. reported Q4 2024 revenue and EPS beats, driven by strong Keytruda sales, but 2025 guidance fell short of consensus estimates due to paused Gardasil sales in China and lower Winrevair sales. The looming 2028 Keytruda loss of exclusivity remains a key concern, with analysts projecting a 10-20% sales decline, though a subcutaneous formulation aims to mitigate this; the company's pipeline and strategic M&A are crucial for long-term growth, but analysts have mixed reactions to Merck's current approach.

Analysis

Merck & Co. delivered a mixed financial picture, with fourth-quarter 2024 results surpassing expectations (1% revenue beat, 7% EPS beat, $15.6 billion total revenue, $1.72 non-GAAP diluted EPS) driven by Keytruda's continued strength ($7.84 billion sales, 3% consensus beat). However, this positive performance is overshadowed by cautious 2025 guidance, projecting revenue between $64.1 billion and $65.6 billion (3% below consensus) and EPS of $8.88 to $9.03 (2.2% below consensus), reflecting significant headwinds. These headwinds include a pause in Gardasil sales in China through mid-2025 due to distributor inventory and working capital issues, which has drastically reduced 2025 China revenue projections for the vaccine from $2 billion to a $0-$1 billion range, and Winrevair sales of $200 million missing consensus by 6%, although this underperformance is attributed by analysts to inflated market expectations rather than poor demand. The impending 2028 loss of exclusivity for Keytruda, which could precipitate a 10-20% sales decline, remains the paramount long-term concern for Merck. While the company aims to mitigate this exposure through a subcutaneous Keytruda formulation (regulatory filings submitted, approval anticipated by 2025 with a projected 30-40% conversion rate), its ultimate success and ability to fend off biosimilar competition are yet uncertain. Merck's pipeline, featuring candidates such as enlicitide for cholesterol management and clesrovimab awaiting FDA approval, offers potential for long-term growth expected to scale commercially after 2025, but the company's business development and M&A strategy has been perceived as cautious by some analysts, despite a strong balance sheet allowing for strategic flexibility. The overall sentiment for MRK is slightly negative (-0.2), reflecting these mixed signals and the fact that ten analysts have recently revised their earnings estimates downward for the upcoming period, despite last-twelve-months revenue growth of 4.1%.

Key Decisions for Investors

• Investors should closely scrutinize Merck's progress in resolving Gardasil sales disruptions in China and the market adoption of the subcutaneous Keytruda formulation, expected post-2025 approval, as key indicators for near-to-medium term performance.
• Careful evaluation of Merck's pipeline commercialization success after 2025 and its execution of strategic M&A is crucial to assess its capacity to mitigate the impact of Keytruda's 2028 patent expiration.
• Given the cautious 2025 guidance, downward analyst revisions, and the significant Keytruda LOE risk, a balanced approach is warranted, weighing these headwinds against the company's strong balance sheet and long-term pipeline opportunities before making significant investment decisions.